首页 > 最新文献

International Journal of Drug Policy最新文献

英文 中文
Recruiting opioid treatment program administrators for a national survey: Outcomes and lessons learned
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-06 DOI: 10.1016/j.drugpo.2025.104799
Benjamin R Brady , Beth E Meyerson , Alissa Davis , Greg A Carter , Sara Najar , Alexa Martinez , Caleb Mueller , Elias O Higbie , Holden Dal Ponte , Khino Moneva , Natalia C Bentz , Linnea B Linde-Krieger , Zhanette Coffee , Arlene N Mahoney , David Frank , Richard A Crosby

Background

Globally, access to opioid use disorder treatment remains insufficient. In the US, recent policy changes for opioid use disorder treatment present opportunities to improve patient access to evidence-based methadone treatment. To evaluate the adoption and sustained implementation of these changes, access to a national, representative sample of opioid treatment programs (OTPs, ‘methadone clinics’) is essential. This study reports the outcomes of a recruitment effort for a national sample of OTP administrators.

Methods

A stratified random sample of 1000 OTPs was drawn from the US Substance Abuse and Mental Health Services Administration's National Opioid Treatment Program Directory. Stratification was based on state-level OTP regulations and county-level opioid overdose rates. OTPs identified as tribal serving, located in jails or prisons, or requiring corporate approval for research participation were deemed ineligible and excluded from the sample. A team of trained researchers called OTP clinics seeking to speak with administrators and obtain their email addresses for study recruitment.

Results

In the sample, 885 OTPs were eligible for study recruitment. We contacted a live person by phone at 73 % of OTPs and an administrator at 23 %. Of the administrators reached, 77 % agreed to receive study information and 22 % completed the survey. Total caller time was 276.5 hours at a cost of $5530.

Conclusion

Despite a rigorous sampling frame, and a costly and considerable effort, US OTP recruitment outcomes were suboptimal. Innovative strategies are needed to improve administrator recruitment. Recommendations include updating the SAMHSA directory to include administrator contact information (name, phone, email), using diverse outreach methods, and refining call scripts to improve engagement.
{"title":"Recruiting opioid treatment program administrators for a national survey: Outcomes and lessons learned","authors":"Benjamin R Brady ,&nbsp;Beth E Meyerson ,&nbsp;Alissa Davis ,&nbsp;Greg A Carter ,&nbsp;Sara Najar ,&nbsp;Alexa Martinez ,&nbsp;Caleb Mueller ,&nbsp;Elias O Higbie ,&nbsp;Holden Dal Ponte ,&nbsp;Khino Moneva ,&nbsp;Natalia C Bentz ,&nbsp;Linnea B Linde-Krieger ,&nbsp;Zhanette Coffee ,&nbsp;Arlene N Mahoney ,&nbsp;David Frank ,&nbsp;Richard A Crosby","doi":"10.1016/j.drugpo.2025.104799","DOIUrl":"10.1016/j.drugpo.2025.104799","url":null,"abstract":"<div><h3>Background</h3><div>Globally, access to opioid use disorder treatment remains insufficient. In the US, recent policy changes for opioid use disorder treatment present opportunities to improve patient access to evidence-based methadone treatment. To evaluate the adoption and sustained implementation of these changes, access to a national, representative sample of opioid treatment programs (OTPs, ‘methadone clinics’) is essential. This study reports the outcomes of a recruitment effort for a national sample of OTP administrators.</div></div><div><h3>Methods</h3><div>A stratified random sample of 1000 OTPs was drawn from the US Substance Abuse and Mental Health Services Administration's National Opioid Treatment Program Directory. Stratification was based on state-level OTP regulations and county-level opioid overdose rates. OTPs identified as tribal serving, located in jails or prisons, or requiring corporate approval for research participation were deemed ineligible and excluded from the sample. A team of trained researchers called OTP clinics seeking to speak with administrators and obtain their email addresses for study recruitment.</div></div><div><h3>Results</h3><div>In the sample, 885 OTPs were eligible for study recruitment. We contacted a live person by phone at 73 % of OTPs and an administrator at 23 %. Of the administrators reached, 77 % agreed to receive study information and 22 % completed the survey. Total caller time was 276.5 hours at a cost of $5530.</div></div><div><h3>Conclusion</h3><div>Despite a rigorous sampling frame, and a costly and considerable effort, US OTP recruitment outcomes were suboptimal. Innovative strategies are needed to improve administrator recruitment. Recommendations include updating the SAMHSA directory to include administrator contact information (name, phone, email), using diverse outreach methods, and refining call scripts to improve engagement.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104799"},"PeriodicalIF":4.4,"publicationDate":"2025-04-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143784003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Experiences of stigmatization among people who use drugs in the initial year of British Columbia's drug decriminalization policy: A qualitative study
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-05 DOI: 10.1016/j.drugpo.2025.104791
Farihah Ali , Cayley Russell , Savannah Torres-Salbach , Margret Lo , Matthew Bonn , Geoff Bardwell , Juls Budau , Elaine Hyshka , Jürgen Rehm

Background

On January 31, 2023, Health Canada approved a three-year pilot decriminalization initiative allowing adults in British Columbia (BC), Canada, to legally possess a cumulative 2.5 g of opioids, cocaine, methamphetamine, or MDMA. The policy aims to reduce the harms associated with drug use, including stigma, which contributes to barriers for people who use drugs in accessing harm reduction and treatment services. Addressing stigma is considered a crucial step in mitigating BC's overdose crisis, by encouraging people who use drugs to feel more comfortable to access and utilize services without fear of judgment. This study examined the impacts of the decriminalization policy on stigma among people who use drugs within the first year of implementation.

Methods

From October 2023 to February 2024, 100 semi-structured telephone interviews and brief socio-demographic surveys with people who use drugs from across BC were conducted to explore their experiences of stigmatization post-decriminalization. A qualitative thematic analysis was used to synthesize the data.

Results

Findings revealed that societal, structural and self-stigma remain pervasive among people who use drugs post-decriminalization. While most participants reported little change in their experiences of stigma since the policy's implementation, some reported an increase, while others observed a decrease across all forms of stigma. Increased stigma was attributed to perceived heightened visibility of public drug use, which amplified societal stigma. Conversely, decreased stigma was linked to shifting public perceptions of drug use as a public health issue and more humanized interactions with the police. Despite mixed experiences, participants remained optimistic that the policy could contribute to long-term stigma reduction and offered recommendations to support this goal.

Conclusion

While decriminalization has the potential to reduce stigma and increase comfort in accessing critical harm reduction and substance use treatment services among people who use drugs, achieving these outcomes requires additional efforts. Public awareness campaigns, targeted anti-stigma education, and broader systemic changes were suggested by participants as essential to address stigmatization in BC. Strengthening these areas could enhance access to and utilization of services, ultimately supporting the broader goals of decriminalization.
{"title":"Experiences of stigmatization among people who use drugs in the initial year of British Columbia's drug decriminalization policy: A qualitative study","authors":"Farihah Ali ,&nbsp;Cayley Russell ,&nbsp;Savannah Torres-Salbach ,&nbsp;Margret Lo ,&nbsp;Matthew Bonn ,&nbsp;Geoff Bardwell ,&nbsp;Juls Budau ,&nbsp;Elaine Hyshka ,&nbsp;Jürgen Rehm","doi":"10.1016/j.drugpo.2025.104791","DOIUrl":"10.1016/j.drugpo.2025.104791","url":null,"abstract":"<div><h3>Background</h3><div>On January 31, 2023, Health Canada approved a three-year pilot decriminalization initiative allowing adults in British Columbia (BC), Canada, to legally possess a cumulative 2.5 g of opioids, cocaine, methamphetamine, or MDMA. The policy aims to reduce the harms associated with drug use, including stigma, which contributes to barriers for people who use drugs in accessing harm reduction and treatment services. Addressing stigma is considered a crucial step in mitigating BC's overdose crisis, by encouraging people who use drugs to feel more comfortable to access and utilize services without fear of judgment. This study examined the impacts of the decriminalization policy on stigma among people who use drugs within the first year of implementation.</div></div><div><h3>Methods</h3><div>From October 2023 to February 2024, 100 semi-structured telephone interviews and brief socio-demographic surveys with people who use drugs from across BC were conducted to explore their experiences of stigmatization post-decriminalization. A qualitative thematic analysis was used to synthesize the data.</div></div><div><h3>Results</h3><div>Findings revealed that societal, structural and self-stigma remain pervasive among people who use drugs post-decriminalization. While most participants reported little change in their experiences of stigma since the policy's implementation, some reported an increase, while others observed a decrease across all forms of stigma. Increased stigma was attributed to perceived heightened visibility of public drug use, which amplified societal stigma. Conversely, decreased stigma was linked to shifting public perceptions of drug use as a public health issue and more humanized interactions with the police. Despite mixed experiences, participants remained optimistic that the policy could contribute to long-term stigma reduction and offered recommendations to support this goal.</div></div><div><h3>Conclusion</h3><div>While decriminalization has the potential to reduce stigma and increase comfort in accessing critical harm reduction and substance use treatment services among people who use drugs, achieving these outcomes requires additional efforts. Public awareness campaigns, targeted anti-stigma education, and broader systemic changes were suggested by participants as essential to address stigmatization in BC. Strengthening these areas could enhance access to and utilization of services, ultimately supporting the broader goals of decriminalization.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104791"},"PeriodicalIF":4.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777445","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Transnational alcohol corporations in Nigeria as commercial determinants of health: Implications for policy
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-05 DOI: 10.1016/j.drugpo.2025.104792
Emeka W. Dumbili
Research on commercial determinants of health (CDoH) has burgeoned in the Global North. However, despite the heavy presence of harmful commodity industries in Africa, little scholarly attention has been paid to CDoH. Transnational alcohol corporations (TNACs) in Nigeria deploy well-articulated marketing strategies and practices that negatively impact health in their quest for profit maximisation, wealth extraction and influence. Nevertheless, their tactics and practices are largely unregulated and understudied. This commentary demonstrates how TNACs in Nigeria are a key pervasive and harmful CDoH, highlighting the policy implications of their strategies and practices. Focusing on changing norms that constrain young people's drinking, TNACs promote hazardous drinking practices by using drinking games as a marketing strategy where the winners receive more alcohol and money as prizes. Alcohol corporations also encourage sexual risk-taking and associated harm by marketing alcoholic bitters as aphrodisiacs and sex enhancers. From 2014 to 2016, one TNAC organised the annual Nigerian Beer Symposium, spreading misleading information that beer consumption prevents cancer, reduces kidney stones, and improves women's skin beauty. Furthermore, through partnerships with the government, TNACs appear to use industry-led corporate social responsibility (CSR) initiatives to lobby officials, enhance corporate reputations, sustain pro-drinking framings, disinformation/misinformation and self-regulation, and silence discussions on alcohol policy implementation. While TNACs’ products and practices negatively impact health/equities, decision-makers appear to enable their enormous power. The government should embrace evidence against TNACs as CDoH, implement policies to regulate them and collaborate with civil society organisations/advocates to hold them to account. Relatedly, the government should hold TNACs to account through international mechanisms because most of their practices violate laws in the Global North countries where they are headquartered.
关于健康的商业决定因素(CDoH)的研究在全球北方地区蓬勃发展。然而,尽管非洲存在大量有害的商品行业,学术界却很少关注商业决定健康因素。尼日利亚的跨国酒类公司(TNACs)在追求利润最大化、攫取财富和扩大影响的过程中,采取了对健康产生负面影响的精心策划的营销策略和做法。然而,它们的策略和做法在很大程度上不受监管,也未得到充分研究。本评论阐述了尼日利亚的 TNACs 是如何成为一种普遍存在且有害的 CDoH 的,并强调了其策略和做法对政策的影响。TNACs 注重改变限制年轻人饮酒的规范,将饮酒游戏作为一种营销策略,获胜者可以获得更多的酒和金钱作为奖品,从而推广有害饮酒行为。酒类公司还将苦味酒作为春药和性兴奋剂进行营销,从而鼓励性冒险和相关伤害。从 2014 年到 2016 年,一家 TNAC 组织了一年一度的尼日利亚啤酒研讨会,传播误导性信息,称饮用啤酒可以预防癌症、减少肾结石、改善女性皮肤美容。此外,通过与政府合作,TNACs似乎还利用行业主导的企业社会责任(CSR)活动游说官员,提高企业声誉,维持支持饮酒的框架、虚假信息/误导信息和自律,并压制有关酒类政策实施的讨论。尽管 TNAC 的产品和行为对健康/权益造成了负面影响,但决策者似乎仍在助长其巨大的势力。作为 CDoH,政府应采纳针对 TNAC 的证据,实施政策对其进行监管,并与民间组织/倡导者合作,追究其责任。与此相关,政府应通过国际机制追究跨国医疗集团的责任,因为它们的大多数做法都违反了其总部所在的北半球国家的法律。
{"title":"Transnational alcohol corporations in Nigeria as commercial determinants of health: Implications for policy","authors":"Emeka W. Dumbili","doi":"10.1016/j.drugpo.2025.104792","DOIUrl":"10.1016/j.drugpo.2025.104792","url":null,"abstract":"<div><div>Research on commercial determinants of health (CDoH) has burgeoned in the Global North. However, despite the heavy presence of harmful commodity industries in Africa, little scholarly attention has been paid to CDoH. Transnational alcohol corporations (TNACs) in Nigeria deploy well-articulated marketing strategies and practices that negatively impact health in their quest for profit maximisation, wealth extraction and influence. Nevertheless, their tactics and practices are largely unregulated and understudied. This commentary demonstrates how TNACs in Nigeria are a key pervasive and harmful CDoH, highlighting the policy implications of their strategies and practices. Focusing on changing norms that constrain young people's drinking, TNACs promote hazardous drinking practices by using drinking games as a marketing strategy where the winners receive more alcohol and money as prizes. Alcohol corporations also encourage sexual risk-taking and associated harm by marketing <em>alcoholic bitters</em> as aphrodisiacs and sex enhancers. From 2014 to 2016, one TNAC organised the annual Nigerian Beer Symposium, spreading misleading information that beer consumption prevents cancer, reduces kidney stones, and improves women's skin beauty. Furthermore, through partnerships with the government, TNACs appear to use industry-led corporate social responsibility (CSR) initiatives to lobby officials, enhance corporate reputations, sustain pro-drinking framings, disinformation/misinformation and self-regulation, and silence discussions on alcohol policy implementation. While TNACs’ products and practices negatively impact health/equities, decision-makers appear to enable their enormous power. The government should embrace evidence against TNACs as CDoH, implement policies to regulate them and collaborate with civil society organisations/advocates to hold them to account. Relatedly, the government should hold TNACs to account through international mechanisms because most of their practices violate laws in the Global North countries where they are headquartered.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":""},"PeriodicalIF":4.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143776597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-05 DOI: 10.1016/j.drugpo.2025.104793
André J. McDonald , Alysha Cooper , Amanda Doggett , Jillian Halladay , Kyla Belisario , James MacKillop

Background

Recreational cannabis legalization (RCL) is being adopted by a growing number of jurisdictions internationally. RCL aims to displace the illegal cannabis market and has the potential to disrupt the medical market, yet few studies have examined these dynamics empirically.

Methods

We used interrupted time series analysis to evaluate whether RCL (legislative passage in October 2017/implementation in October 2018) was associated with changes in quarterly national household expenditures on medical cannabis, illegal cannabis, and all cannabis types combined (licensed, illegal, and medical) in Canada from 2001 to 2023, adjusting for price fluctuations.

Results

When RCL was passed, medical cannabis represented 11.8 % of the market and illegal cannabis 88.2 %. At five years post-RCL implementation, medical cannabis decreased to 3.7 %, illegal cannabis decreased to 24.3 %, and licensed cannabis took over 72.0 % of the market. The overall cannabis market increased in size by 75 % over these 5 years. Illegal cannabis expenditures increased between RCL passage and implementation but decreased immediately post-implementation and had a significant decreasing trend. Medical cannabis had a significant decreasing trend following RCL passage, and to a lesser extent following RCL implementation. Total cannabis expenditures increased immediately following RCL implementation and showed a significant increasing trend over time. Some caution should be used in interpreting these findings given uncertainty in data quality, particularly for illegal cannabis expenditures (and overall expenditures by extension).

Conclusions

Recreational cannabis legalization in Canada appears to be achieving one of its primary goals by displacing the illegal cannabis market, and medical users also appear to be transitioning to the recreational market. However, overall cannabis expenditures have also grown substantially since legalization, which could have adverse implications for public health.
{"title":"Association of recreational cannabis legalization with changes in medical, illegal, and total cannabis expenditures in Canada","authors":"André J. McDonald ,&nbsp;Alysha Cooper ,&nbsp;Amanda Doggett ,&nbsp;Jillian Halladay ,&nbsp;Kyla Belisario ,&nbsp;James MacKillop","doi":"10.1016/j.drugpo.2025.104793","DOIUrl":"10.1016/j.drugpo.2025.104793","url":null,"abstract":"<div><h3>Background</h3><div>Recreational cannabis legalization (RCL) is being adopted by a growing number of jurisdictions internationally. RCL aims to displace the illegal cannabis market and has the potential to disrupt the medical market, yet few studies have examined these dynamics empirically.</div></div><div><h3>Methods</h3><div>We used interrupted time series analysis to evaluate whether RCL (legislative passage in October 2017/implementation in October 2018) was associated with changes in quarterly national household expenditures on medical cannabis, illegal cannabis, and all cannabis types combined (licensed, illegal, and medical) in Canada from 2001 to 2023, adjusting for price fluctuations.</div></div><div><h3>Results</h3><div>When RCL was passed, medical cannabis represented 11.8 % of the market and illegal cannabis 88.2 %. At five years post-RCL implementation, medical cannabis decreased to 3.7 %, illegal cannabis decreased to 24.3 %, and licensed cannabis took over 72.0 % of the market. The overall cannabis market increased in size by 75 % over these 5 years. Illegal cannabis expenditures increased between RCL passage and implementation but decreased immediately post-implementation and had a significant decreasing trend. Medical cannabis had a significant decreasing trend following RCL passage, and to a lesser extent following RCL implementation. Total cannabis expenditures increased immediately following RCL implementation and showed a significant increasing trend over time. Some caution should be used in interpreting these findings given uncertainty in data quality, particularly for illegal cannabis expenditures (and overall expenditures by extension).</div></div><div><h3>Conclusions</h3><div>Recreational cannabis legalization in Canada appears to be achieving one of its primary goals by displacing the illegal cannabis market, and medical users also appear to be transitioning to the recreational market. However, overall cannabis expenditures have also grown substantially since legalization, which could have adverse implications for public health.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104793"},"PeriodicalIF":4.4,"publicationDate":"2025-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143777446","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of Delta-8-THC warning labels on perceived intoxication, harm, and susceptibility among adolescents
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-04 DOI: 10.1016/j.drugpo.2025.104781
Alyssa F. Harlow , Adam M. Leventhal , Jessica L. Barrington-Trimis

Background

Youth use of hemp-derived cannabis products containing psychoactive Δ8-tetrahydrocannabinol (delta-8-THC) is prevalent in the United States (US). Delta-8-THC is intoxicating, however delta-8-THC products are not subject to warning labeling requirements in many US states. This experiment determined effects of hypothetical cannabis warning labels on perception of delta-8-THC gummies and vape products.

Methods

A mixed within-between-subject experiment was embedded into a 2023 survey of 3,647 Southern California adolescents. Participants were randomized to view photos of delta-8-THC edible and vape products under one of three conditions (control [unmodified] vs. standard size warning label [universal cannabis warning symbol, government warning text, instructions for use, and text stating it was cannabis-infused] vs. larger warning label [same as standard label with larger cannabis warning symbol]). After image exposure, we measured anticipated intoxication, perceived harm, and susceptibility to use the respective delta-8-THC products. Moderation by product type and cannabis use status were assessed.

Results

Youth who viewed delta-8-THC products with larger warning labels (vs. control) reported greater anticipated intoxication (Mean Difference[MD]==2.50, 95 %CI=0.85–4.14 on 100-point scale), and higher likelihood that delta-8-THC products are bad for their health (Risk Ratio[RR]=1.07, 95 %CI=1.02–1.12), pose at least some risk (RR=1.03, 95 %CI: 1.01–1.05), and are the same or more harmful than marijuana (RR=1.04, 95 %CI=1.01–1.07). There were no warning label effects on susceptibility and minimal differences across outcomes between larger versus standard warning labels. Warning label effects on perceived harm were stronger for delta-8-THC gummies (vs. vape) and for never vs. ever cannabis-using youth (interaction p-values < 0.05).

Conclusion

Requiring delta-8-THC products to conform to labeling requirements for cannabis products may increase understanding of their intoxicating effects and harm among cannabis-naïve youth. In lieu of federal regulations, states should consider implementation of delta-8-THC regulations such as labeling requirements that promote safety and reduce potential harm to youth.
{"title":"Impact of Delta-8-THC warning labels on perceived intoxication, harm, and susceptibility among adolescents","authors":"Alyssa F. Harlow ,&nbsp;Adam M. Leventhal ,&nbsp;Jessica L. Barrington-Trimis","doi":"10.1016/j.drugpo.2025.104781","DOIUrl":"10.1016/j.drugpo.2025.104781","url":null,"abstract":"<div><h3>Background</h3><div>Youth use of hemp-derived cannabis products containing psychoactive Δ8-tetrahydrocannabinol (delta-8-THC) is prevalent in the United States (US). Delta-8-THC is intoxicating, however delta-8-THC products are not subject to warning labeling requirements in many US states. This experiment determined effects of hypothetical cannabis warning labels on perception of delta-8-THC gummies and vape products.</div></div><div><h3>Methods</h3><div>A mixed within-between-subject experiment was embedded into a 2023 survey of 3,647 Southern California adolescents. Participants were randomized to view photos of delta-8-THC edible and vape products under one of three conditions (control [unmodified] vs. standard size warning label [universal cannabis warning symbol, government warning text, instructions for use, and text stating it was cannabis-infused] vs. larger warning label [same as standard label with larger cannabis warning symbol]). After image exposure, we measured anticipated intoxication, perceived harm, and susceptibility to use the respective delta-8-THC products. Moderation by product type and cannabis use status were assessed.</div></div><div><h3>Results</h3><div>Youth who viewed delta-8-THC products with larger warning labels (vs. control) reported greater anticipated intoxication (Mean Difference[MD]==2.50, 95 %CI=0.85–4.14 on 100-point scale), and higher likelihood that delta-8-THC products are bad for their health (Risk Ratio[RR]=1.07, 95 %CI=1.02–1.12), pose at least some risk (RR=1.03, 95 %CI: 1.01–1.05), and are the same or more harmful than marijuana (RR=1.04, 95 %CI=1.01–1.07). There were no warning label effects on susceptibility and minimal differences across outcomes between larger versus standard warning labels. Warning label effects on perceived harm were stronger for delta-8-THC gummies (vs. vape) and for never vs. ever cannabis-using youth (interaction p-values &lt; 0.05).</div></div><div><h3>Conclusion</h3><div>Requiring delta-8-THC products to conform to labeling requirements for cannabis products may increase understanding of their intoxicating effects and harm among cannabis-naïve youth. In lieu of federal regulations, states should consider implementation of delta-8-THC regulations such as labeling requirements that promote safety and reduce potential harm to youth.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104781"},"PeriodicalIF":4.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143769005","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Structural and healthcare predictors of substance use-related death following release from incarceration: A retrospective cohort study in Rhode Island, 2018–2020
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-04 DOI: 10.1016/j.drugpo.2025.104783
Lauren Brinkley-Rubinstein , Katherine LeMasters , Justin Berk , Sara N. Levintow , Sarah Martino , Rahul Vanjani

Background

Incarcerated individuals are at a high risk of substance use-related death after release. While prior research has demonstrated that this is partially due to loss of tolerance during incarceration and return to use after release, structural and healthcare use factors that may also impact overdose risk have been underexplored. We assessed the relationship between structural factors (e.g., housing services received) and health care use (e.g., emergency department use) and overdose risk at 12-months post-incarceration in Rhode Island in the United States.

Methods

We used a retrospective cohort study design. Rhode Island Department of Corrections (RIDOC) data were linked with individual-level data across state agencies. Cumulative incidence of substance use-related death was estimated as a function of structural and healthcare factors using hazard ratios from cause-specific cox landmark models for dynamic predictions.

Results

There were 9696 individuals in the analytic sample. Most deaths that occurred within 12 months post-release involved substance use (N = 96). People who had more previous incarcerations had a higher risk of substance use-related death. Reporting taxable wages (aHR: 0.52; 95 % CI: 0.25, 1.09) was weakly associated with in a lower risk of substance use-related death while being admitted to the hospital (aHR: 1.79; 95 % CI: 0.91, 3.53) was weakly associated with a slightly higher risk of substance use-related death 12-months post-release.

Conclusion

Structural factors were weakly associated with reduced risk of substance use-related death post-release from incarceration. Conducting needs assessments (e.g., identifying employment needs) and interventions (e.g., employment training programs) prior to or at release that address these structural factors are critical for reducing this risk. Further, these findings contribute to the evidence that decarceration should be used a public health tool given the high risk of substance use-related death post-release.
背景被监禁者获释后发生与药物使用相关的死亡的风险很高。先前的研究表明,造成这种情况的部分原因是在监禁期间丧失了耐受性,出狱后又重新使用药物,但对可能影响用药过量风险的结构性因素和医疗保健使用因素的研究还不够。我们评估了美国罗德岛州入狱后 12 个月内结构性因素(如接受的住房服务)和医疗保健使用(如急诊室使用)与用药过量风险之间的关系。我们采用了回顾性队列研究设计,将罗德岛惩教署(RIDOC)的数据与各州机构的个人数据进行了关联。使用特定病因 cox 地标模型的危险比进行动态预测,将药物使用相关死亡的累积发生率估算为结构和医疗保健因素的函数。释放后 12 个月内发生的死亡大多与药物使用有关(N = 96)。曾被监禁次数越多的人与药物使用相关的死亡风险越高。报告应税工资(aHR:0.52;95 % CI:0.25, 1.09)与药物使用相关死亡风险较低关系不大,而入院(aHR:1.79;95 % CI:0.91, 3.53)与释放后 12 个月内药物使用相关死亡风险略高关系不大。在释放前或释放时进行需求评估(如确定就业需求)和干预(如就业培训计划),以解决这些结构性因素,对于降低这种风险至关重要。此外,鉴于释放后与药物使用相关的死亡风险很高,这些研究结果有助于证明应将非监禁作为一种公共卫生工具来使用。
{"title":"Structural and healthcare predictors of substance use-related death following release from incarceration: A retrospective cohort study in Rhode Island, 2018–2020","authors":"Lauren Brinkley-Rubinstein ,&nbsp;Katherine LeMasters ,&nbsp;Justin Berk ,&nbsp;Sara N. Levintow ,&nbsp;Sarah Martino ,&nbsp;Rahul Vanjani","doi":"10.1016/j.drugpo.2025.104783","DOIUrl":"10.1016/j.drugpo.2025.104783","url":null,"abstract":"<div><h3>Background</h3><div>Incarcerated individuals are at a high risk of substance use-related death after release. While prior research has demonstrated that this is partially due to loss of tolerance during incarceration and return to use after release, structural and healthcare use factors that may also impact overdose risk have been underexplored. We assessed the relationship between structural factors (e.g., housing services received) and health care use (e.g., emergency department use) and overdose risk at 12-months post-incarceration in Rhode Island in the United States.</div></div><div><h3>Methods</h3><div>We used a retrospective cohort study design. Rhode Island Department of Corrections (RIDOC) data were linked with individual-level data across state agencies. Cumulative incidence of substance use-related death was estimated as a function of structural and healthcare factors using hazard ratios from cause-specific cox landmark models for dynamic predictions.</div></div><div><h3>Results</h3><div>There were 9696 individuals in the analytic sample. Most deaths that occurred within 12 months post-release involved substance use (<em>N</em> = 96). People who had more previous incarcerations had a higher risk of substance use-related death. Reporting taxable wages (aHR: 0.52; 95 % CI: 0.25, 1.09) was weakly associated with in a lower risk of substance use-related death while being admitted to the hospital (aHR: 1.79; 95 % CI: 0.91, 3.53) was weakly associated with a slightly higher risk of substance use-related death 12-months post-release.</div></div><div><h3>Conclusion</h3><div>Structural factors were weakly associated with reduced risk of substance use-related death post-release from incarceration. Conducting needs assessments (e.g., identifying employment needs) and interventions (e.g., employment training programs) prior to or at release that address these structural factors are critical for reducing this risk. Further, these findings contribute to the evidence that decarceration should be used a public health tool given the high risk of substance use-related death post-release.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104783"},"PeriodicalIF":4.4,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143769004","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prioritising research on marketing and consumption of No and Low (NoLo) alcoholic beverages in Ireland
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-03 DOI: 10.1016/j.drugpo.2025.104794
Emeka W. Dumbili , Paula Leonard , James Larkin , Frank Houghton
Advertising of zero/no and low-strength (NoLo) alcohol brands is becoming increasingly common in Ireland, but empirical research to determine their impact is lacking. Although the Public Health (Alcohol) Act (2018) prohibits advertising alcohol on or within 200 m of buses, trains, schools and playgrounds, the alcohol industry advertises NoLo products in these spaces using similar iconography and brand identifiers of parent brands. This article highlights evidence regarding the industry's roles in the frequent promotion of NoLo brands in Ireland, recommending areas for future research. While NoLo products and advertisements are becoming common in Ireland, recently, the alcohol industry invested €30 million to double NoLo's production capacity. Given the available evidence elsewhere, we argue that doubling the production capacity serves the alcohol industry's interests, not public health interests, as it misleadingly claims because it will increase alcogenic environments and exposure to more marketing campaigns and normalise alcohol consumption. We urge the Minister of Health to take responsibility for effectively interpreting and implementing the Public Health Act to ban NoLo advertising in spaces where full-strength beverage advertisements are prohibited. We conclude by recommending key areas for urgent research focusing on, but not limited to, the perceptions and consumption of NoLo among different populations, including those who drink harmfully or are in recovery and the impact of marketing and availability of NoLo on alcohol initiation and consumption among young people. This will help generate robust evidence to inform the public, improve public health, and implement policies that curtail alcohol corporations’ health-damaging activities in Ireland.
零度/无度和低度(NoLo)酒精品牌的广告在爱尔兰越来越常见,但却缺乏确定其影响的实证研究。尽管《公共健康(酒精)法案》(2018 年)禁止在公共汽车、火车、学校和游乐场上或 200 米范围内发布酒精广告,但酒精行业仍在这些场所使用类似母品牌的图标和品牌标识为 NoLo 产品做广告。本文重点介绍了酒类行业在爱尔兰频繁推广 NoLo 品牌中所扮演的角色,并就未来研究领域提出了建议。虽然 NoLo 产品和广告在爱尔兰越来越常见,但最近酒类行业投资 3000 万欧元将 NoLo 的产能翻了一番。鉴于其他地方的现有证据,我们认为,产能翻倍符合酒精行业的利益,而不是其误导性声称的公共健康利益,因为这将增加酒精环境,接触更多的营销活动,并使酒精消费正常化。我们敦促卫生部长负起责任,有效解释和执行《公共卫生法》,禁止在禁止全烈性饮料广告的场所发布 NoLo 广告。最后,我们建议开展关键领域的紧急研究,重点关注但不限于不同人群对 NoLo 的看法和消费情况,包括有害饮酒者或戒酒者,以及 NoLo 的营销和供应对年轻人开始饮酒和饮酒的影响。这将有助于生成有力的证据,以向公众提供信息,改善公共卫生,并实施政策,遏制酒精公司在爱尔兰开展的损害健康的活动。
{"title":"Prioritising research on marketing and consumption of No and Low (NoLo) alcoholic beverages in Ireland","authors":"Emeka W. Dumbili ,&nbsp;Paula Leonard ,&nbsp;James Larkin ,&nbsp;Frank Houghton","doi":"10.1016/j.drugpo.2025.104794","DOIUrl":"10.1016/j.drugpo.2025.104794","url":null,"abstract":"<div><div>Advertising of zero/no and low-strength (NoLo) alcohol brands is becoming increasingly common in Ireland, but empirical research to determine their impact is lacking. Although the Public Health (Alcohol) Act (2018) prohibits advertising alcohol on or within 200 m of buses, trains, schools and playgrounds, the alcohol industry advertises NoLo products in these spaces using similar iconography and brand identifiers of parent brands. This article highlights evidence regarding the industry's roles in the frequent promotion of NoLo brands in Ireland, recommending areas for future research. While NoLo products and advertisements are becoming common in Ireland, recently, the alcohol industry invested €30 million to double NoLo's production capacity. Given the available evidence elsewhere, we argue that doubling the production capacity serves the alcohol industry's interests, not public health interests, as it misleadingly claims because it will increase alcogenic environments and exposure to more marketing campaigns and normalise alcohol consumption. We urge the Minister of Health to take responsibility for effectively interpreting and implementing the Public Health Act to ban NoLo advertising in spaces where full-strength beverage advertisements are prohibited. We conclude by recommending key areas for urgent research focusing on, but not limited to, the perceptions and consumption of NoLo among different populations, including those who drink harmfully or are in recovery and the impact of marketing and availability of NoLo on alcohol initiation and consumption among young people. This will help generate robust evidence to inform the public, improve public health, and implement policies that curtail alcohol corporations’ health-damaging activities in Ireland.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104794"},"PeriodicalIF":4.4,"publicationDate":"2025-04-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143761045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Standard THC units: A tool to benchmark cannabis-related driving risks
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-02 DOI: 10.1016/j.drugpo.2025.104788
Valentina Lorenzetti , Tom P Freeman , Amie Hayley
{"title":"Standard THC units: A tool to benchmark cannabis-related driving risks","authors":"Valentina Lorenzetti ,&nbsp;Tom P Freeman ,&nbsp;Amie Hayley","doi":"10.1016/j.drugpo.2025.104788","DOIUrl":"10.1016/j.drugpo.2025.104788","url":null,"abstract":"","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104788"},"PeriodicalIF":4.4,"publicationDate":"2025-04-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143761046","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Community-administered naloxone for overdose reversal: The role of sex worker-led programming and occupational violence in a community-based cohort (2018–2024)
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-04-01 DOI: 10.1016/j.drugpo.2025.104784
Sarah Moreheart , Kate Shannon , Kanna Hayashi , Wiebke Bartels , Andrea Krüsi , Shira Miriam Goldenberg

Background

Amidst the ongoing toxic drug crisis, sex workers who use drugs face high overdose risk alongside structural barriers to harm reduction services. Previous work has noted that occupational violence and peer-led programs can influence health outcomes for sex workers. Given the potential for community-administered take-home naloxone (THN) to reduce overdose-related harm, we evaluated longitudinal trends and uptake of THN administration, and the associations between exposure to sex work-specific programs and occupational violence and harassment with THN administration over 5.5-years (2018–2024).

Methods

Data was derived from An Evaluation of Sex Workers’ Health Access, a prospective, community-based cohort of sex workers in Vancouver, Canada from September 2018-March 2024. We plotted semi-annual trends of THN administration (Aim 1) and used bivariate logistic regression with generalized estimating equations (GEE) to characterize uptake of THN administration (Aim 2). Lastly, we employed bivariate and multivariable GEE to evaluate the association between exposure to sex-work specific programs and occupational violence and harassment with THN administration (Aim 3).

Results

Among 427 participants, 57.9 % (N = 247) reported administering THN at least once. Exposure to sex work-specific programs was strongly associated with THN administration (Adjusted Odds Ratio [AOR] 1.26, 95 % Confidence Interval [CI] 1.02–1.55), as was exposure to violence from clients (AOR 1.72, 95 %CI 1.22–2.41) and community (AOR 1.76, 95 %CI 1.25–2.46), and police harassment (AOR 1.54, 95 %CI 1.07–2.21).

Conclusion

Over 5.5 years, over half of participants administered THN, which was associated with exposure to sex work-specific programs and occupational violence. Violence from clients, community members, and police independently increased the likelihood of THN administration. Findings suggest that marginalized sex workers, particularly those who use drugs in occupational settings, are uniquely positioned to respond to overdoses. This supports the feasibility of implementing sex worker-specific overdose interventions and highlights the need to expand community-based, sex worker-led safety, violence prevention, and care interventions to strengthen overdose prevention efforts and improve naloxone cascade metrics.
{"title":"Community-administered naloxone for overdose reversal: The role of sex worker-led programming and occupational violence in a community-based cohort (2018–2024)","authors":"Sarah Moreheart ,&nbsp;Kate Shannon ,&nbsp;Kanna Hayashi ,&nbsp;Wiebke Bartels ,&nbsp;Andrea Krüsi ,&nbsp;Shira Miriam Goldenberg","doi":"10.1016/j.drugpo.2025.104784","DOIUrl":"10.1016/j.drugpo.2025.104784","url":null,"abstract":"<div><h3>Background</h3><div>Amidst the ongoing toxic drug crisis, sex workers who use drugs face high overdose risk alongside structural barriers to harm reduction services. Previous work has noted that occupational violence and peer-led programs can influence health outcomes for sex workers. Given the potential for community-administered take-home naloxone (THN) to reduce overdose-related harm, we evaluated longitudinal trends and uptake of THN administration, and the associations between exposure to sex work-specific programs and occupational violence and harassment with THN administration over 5.5-years (2018–2024).</div></div><div><h3>Methods</h3><div>Data was derived from An Evaluation of Sex Workers’ Health Access, a prospective, community-based cohort of sex workers in Vancouver, Canada from September 2018-March 2024. We plotted semi-annual trends of THN administration (Aim 1) and used bivariate logistic regression with generalized estimating equations (GEE) to characterize uptake of THN administration (Aim 2). Lastly, we employed bivariate and multivariable GEE to evaluate the association between exposure to sex-work specific programs and occupational violence and harassment with THN administration (Aim 3).</div></div><div><h3>Results</h3><div>Among 427 participants, 57.9 % (N = 247) reported administering THN at least once. Exposure to sex work-specific programs was strongly associated with THN administration (Adjusted Odds Ratio [AOR] 1.26, 95 % Confidence Interval [CI] 1.02–1.55), as was exposure to violence from clients (AOR 1.72, 95 %CI 1.22–2.41) and community (AOR 1.76, 95 %CI 1.25–2.46), and police harassment (AOR 1.54, 95 %CI 1.07–2.21).</div></div><div><h3>Conclusion</h3><div>Over 5.5 years, over half of participants administered THN, which was associated with exposure to sex work-specific programs and occupational violence. Violence from clients, community members, and police independently increased the likelihood of THN administration. Findings suggest that marginalized sex workers, particularly those who use drugs in occupational settings, are uniquely positioned to respond to overdoses. This supports the feasibility of implementing sex worker-specific overdose interventions and highlights the need to expand community-based, sex worker-led safety, violence prevention, and care interventions to strengthen overdose prevention efforts and improve naloxone cascade metrics.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104784"},"PeriodicalIF":4.4,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143746561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia
IF 4.4 2区 医学 Q1 SUBSTANCE ABUSE Pub Date : 2025-03-31 DOI: 10.1016/j.drugpo.2025.104790
Shane Tillakeratne , Heather Valerio , Maryam Alavi , Behzad Hajarizadeh , Marianne Martinello , Jacob George , Gail Matthews , Jason Grebely , Sallie-Anne Pearson , Gregory J. Dore

Background

Monitoring of HCV-related morbidity and mortality is crucial to evaluate direct-acting antiviral (DAA) therapy impact and HCV elimination progress. This population-based study examined mortality among individuals with an HCV notification in New South Wales (NSW), Australia, including cause-specific mortality prior to and during the viral hepatitis elimination era (2015–2021).

Methods

HCV notifications in NSW, Australia (1995–2021) were linked to hospitalisation records and cause-specific mortality records. Over the period 2002–2021, all-cause and cause-specific mortality rates were examined. Cox proportional hazard models were used to assess factors associated with mortality during the viral hepatitis elimination era.

Results

Among people with HCV notifications in 1995–2021, 112,046 were alive during 2002–2021 and contributed to mortality analyses. All-cause mortality per 100,000 population increased from 5.5 in 2002 to 13.4 in 2015 and plateaued at 12.9 in 2021. Liver-related mortality per 100,000 population increased from 2.0 in 2002 to 5.9 in 2015, before declining to 4.6 in 2021. Drug-related mortality per 100,000 population increased from 0.7 in 2002 to 1.8 in 2015, before declining to 1.2 in 2021. Factors associated with increased mortality risk during 2015–2021 included: recent injecting drug use (adjusted Hazard Ratio [aHR] 7.22, 95 % CI 6.84–7.62) and recent alcohol use disorder (aHR 3.17, 95 % CI 2.97–3.37). Recent opioid agonist therapy (aHR 0.47, 95 % CI 0.43–0.51) and recent incarceration (aHR 0.32, 95 % CI 0.23–0.45) were associated with lower mortality risk.

Conclusion

During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality.
{"title":"Trends in cause-specific mortality among people with hepatitis C virus in New South Wales, Australia","authors":"Shane Tillakeratne ,&nbsp;Heather Valerio ,&nbsp;Maryam Alavi ,&nbsp;Behzad Hajarizadeh ,&nbsp;Marianne Martinello ,&nbsp;Jacob George ,&nbsp;Gail Matthews ,&nbsp;Jason Grebely ,&nbsp;Sallie-Anne Pearson ,&nbsp;Gregory J. Dore","doi":"10.1016/j.drugpo.2025.104790","DOIUrl":"10.1016/j.drugpo.2025.104790","url":null,"abstract":"<div><h3>Background</h3><div>Monitoring of HCV-related morbidity and mortality is crucial to evaluate direct-acting antiviral (DAA) therapy impact and HCV elimination progress. This population-based study examined mortality among individuals with an HCV notification in New South Wales (NSW), Australia, including cause-specific mortality prior to and during the viral hepatitis elimination era (2015–2021).</div></div><div><h3>Methods</h3><div>HCV notifications in NSW, Australia (1995–2021) were linked to hospitalisation records and cause-specific mortality records. Over the period 2002–2021, all-cause and cause-specific mortality rates were examined. Cox proportional hazard models were used to assess factors associated with mortality during the viral hepatitis elimination era.</div></div><div><h3>Results</h3><div>Among people with HCV notifications in 1995–2021, 112,046 were alive during 2002–2021 and contributed to mortality analyses. All-cause mortality per 100,000 population increased from 5.5 in 2002 to 13.4 in 2015 and plateaued at 12.9 in 2021. Liver-related mortality per 100,000 population increased from 2.0 in 2002 to 5.9 in 2015, before declining to 4.6 in 2021. Drug-related mortality per 100,000 population increased from 0.7 in 2002 to 1.8 in 2015, before declining to 1.2 in 2021. Factors associated with increased mortality risk during 2015–2021 included: recent injecting drug use (adjusted Hazard Ratio [aHR] 7.22, 95 % CI 6.84–7.62) and recent alcohol use disorder (aHR 3.17, 95 % CI 2.97–3.37). Recent opioid agonist therapy (aHR 0.47, 95 % CI 0.43–0.51) and recent incarceration (aHR 0.32, 95 % CI 0.23–0.45) were associated with lower mortality risk.</div></div><div><h3>Conclusion</h3><div>During the HCV elimination era, both liver-related and drug-related mortality have declined, suggesting direct and indirect impacts of DAA therapy, respectively. Expanded opioid agonist therapy coverage and enhanced alcohol use disorder management could further reduce mortality.</div></div>","PeriodicalId":48364,"journal":{"name":"International Journal of Drug Policy","volume":"139 ","pages":"Article 104790"},"PeriodicalIF":4.4,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143738123","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
International Journal of Drug Policy
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1